公开(公告)号：US20140228568A1

公开(公告)日：2014-08-14

申请号：US13762567

申请日：2013-02-08

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hyunah CHOO ,  Young-Jae KIm ,  Jeeyeon KIM ,  Mi Young YEOM

IPC: C07D241/04

CPC classification number: C07D241/04 ,  C07D295/033 ,  C07D295/073 ,  C07D295/096

Abstract: Provided are biphenyl derivatives exhibiting activity towards central nervous system diseases by acting on the 5-HT7 receptor, pharmaceutically acceptable salts thereof, a method for preparing the compounds and pharmaceutical compositions including the compounds as an active ingredient.

Abstract translation: 提供通过作用于5-HT 7受体，其药学上可接受的盐，制备该化合物的方法和包含该化合物作为活性成分的药物组合物，对中枢神经系统疾病具有活性的联苯衍生物。

公开(公告)号：US20170354650A1

公开(公告)日：2017-12-14

申请号：US15403404

申请日：2017-01-11

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hyunah CHOO ,  Sun-Joon MIN ,  Yun Kyung KIM ,  Hoon RYU ,  Hyemyung SEO ,  Juhyeon KIM ,  Jihoon JANG ,  Sungsu LIM ,  Younghee KIM ,  Yu Jin HWANG ,  Yong Seo CHO

IPC: A61K31/47 ,  A61K31/4709 ,  A61K31/5377

CPC classification number: A61K31/47 ,  A61K31/4709 ,  A61K31/5377

Abstract: The present disclosure relates to a quinoline derivative which inhibits the activity of histone methyltransferases (ESET/SETDB1) specific for the histone molecule H3K9 or a pharmaceutically acceptable salt thereof and a use thereof.

公开(公告)号：US20230390247A1

公开(公告)日：2023-12-07

申请号：US18249401

申请日：2021-09-30

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hyunah CHOO ,  Byungsun JEON ,  Taek KANG ,  Doyoung KIM ,  Jieon LEE

IPC: A61K31/4164 ,  A61K31/40 ,  A61K31/137 ,  A61K9/20 ,  A61K9/48 ,  A61K9/00

CPC classification number: A61K31/4164 ,  A61K31/40 ,  A61K31/137 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2013 ,  A61K9/2059 ,  A61K9/2009 ,  A61K9/4825 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/0019

Abstract: The present disclosure relates to a compound represented by Structural Formula 1 or 2 or a pharmaceutically acceptable salt thereof, for inhibiting the activity of the 5-HT7 serotonin receptor.

公开(公告)号：US20180312509A1

公开(公告)日：2018-11-01

申请号：US15738225

申请日：2017-11-06

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hyunah CHOO ,  Youngjae KIM ,  Jihye SEONG ,  Ghil Soo NAM ,  Yong Seo CHO

IPC: C07D487/04 ,  C07D498/04

CPC classification number: C07D487/04 ,  A61K31/4162 ,  A61K31/55 ,  A61P25/22 ,  A61P25/24 ,  C07D498/04 ,  Y02P20/55

Abstract: Azepine derivatives acting on 5-HT7 receptors and pharmaceutically acceptable salts thereof are disclosed. The azepine derivatives and the pharmaceutically acceptable salts thereof have high binding affinities for and high antagonistic activities on 5-HT7 receptors. Due to these advantages, the azepine derivatives and the pharmaceutically acceptable salts thereof can be applied to therapeutic or prophylactic agents for central nervous system diseases, such as depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, body temperature dysregulation, biorhythm dysregulation, sleep disturbance, and smooth muscle diseases where 5-HT7 receptors antagonistic activity is required.

公开(公告)号：US20140228565A1

公开(公告)日：2014-08-14

申请号：US14038324

申请日：2013-09-26

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hyunah CHOO ,  Sun Joon Min ,  Seon Hee Seo ,  Jee Yeon Kim ,  Yoo Ran Ki ,  Min Joo Kim ,  Sora Kim ,  Youngjae Kim

IPC: C07D495/04

CPC classification number: C07D495/04 ,  A61K31/519

Abstract: Disclosed are thienopyrimidinone derivatives as antagonists that act on metabotropic glutamate receptor subtype 1. The thienopyrimidinone derivatives show pharmacological activity against metabotropic glutamate receptor-related diseases, including pain, such as neuropathic pain and migraine, psychiatric diseases, such as anxiety disorder and schizophrenia, urinary incontinence, and neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease. Also disclosed are methods for preparing the thienopyrimidinone derivatives, and pharmaceutical compositions containing the thienopyrimidinone derivatives as active ingredients.

Abstract translation: 公开了作为代谢型谷氨酸受体亚型1的拮抗剂的噻吩并嘧啶酮衍生物。噻吩并嘧啶酮衍生物显示针对代谢型谷氨酸受体相关疾病的药理学活性，包括疼痛，如神经性疼痛和偏头痛，精神疾病如焦虑障碍和精神分裂症，尿 失禁和神经变性疾病，如帕金森病和阿尔茨海默病。 还公开了制备噻吩并嘧啶酮衍生物的方法和含有噻吩并嘧啶酮衍生物作为活性成分的药物组合物。

公开(公告)号：US20180179130A1

公开(公告)日：2018-06-28

申请号：US15653970

申请日：2017-07-19

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hyun Joo LEE ,  Hyunah CHOO ,  Seungmi YEO ,  Tran Huyen DANG ,  Jieon LEE ,  Soon Hyeok HONG ,  Dabon LEE ,  Sang Deuk LEE

IPC: C07C29/48 ,  B01J31/22 ,  B01J27/02 ,  C07C31/04

CPC classification number: C07C29/48 ,  B01J27/02 ,  B01J31/226 ,  B01J2531/828 ,  C07C29/12 ,  C07C31/04 ,  C07C303/24 ,  C07C305/06

Abstract: Disclosed is a novel catalyst for producing a methanol precursor. The use of the catalyst enables the production of a methanol precursor and methanol with high efficiency under low temperature and low pressure conditions. Also disclosed are a methanol precursor produced using the catalyst and methanol produced using the methanol precursor.

公开(公告)号：US20180118772A1

公开(公告)日：2018-05-03

申请号：US15399174

申请日：2017-01-05

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hyun Joo LEE ,  Hyunah CHOO ,  Hyejeong LEE ,  Seungmi YEO ,  Moo Seong PARK ,  Soon Hyeok HONG ,  Jaewoon KIM

IPC: C07F15/00 ,  B01J31/18

CPC classification number: C07F15/0093 ,  B01J31/1805 ,  B01J31/1815 ,  B01J2231/40 ,  B01J2231/46 ,  B01J2531/828

Abstract: Disclosed is a novel catalyst having amine ligands for synthesizing methanol or its precursor. When the catalyst is allowed to react with an alkane in the presence of an acid, at least one C—H bond of the alkane is catalytically oxidized. Therefore, the catalyst is suitable for use in forming an alkyl ester from an alkane.

公开(公告)号：US20160244408A1

公开(公告)日：2016-08-25

申请号：US14629821

申请日：2015-02-24

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Hyunah CHOO ,  Gyo Chang KEUM ,  Youngjae KIM ,  MI Young YEOM

IPC: C07D209/86 ,  C07D401/06 ,  C07D413/06 ,  C07D403/06

CPC classification number: C07D209/86 ,  C07D401/06 ,  C07D403/06 ,  C07D413/06

Abstract: Disclosed are carbazole derivatives and pharmaceutically acceptable salts thereof that act on the 5-HT7 receptor. The carbazole derivatives and the pharmaceutically acceptable salts thereof have high binding affinities for the 5-HT7 serotonin receptor and antagonistic activities against the 5-HT7 serotonin receptor. Further disclosed are pharmaceutical compositions including the compounds as active ingredients. The pharmaceutical compositions are useful as therapeutic and prophylactic agents for central nervous system diseases where antagonistic activities against 5-HT7 are required, such as depression, migraine, anxiety, pain, inflammatory pain, neuropathic pain, body temperature dysregulation, circadian rhythm dysregulation, sleep disturbance, and smooth muscle-related diseases.

Abstract translation: 公开了作用于5-HT 7受体的咔唑衍生物及其药学上可接受的盐。 咔唑衍生物及其药学上可接受的盐对5-HT7血清素受体具有高结合亲和力，对5-HT7血清素受体具有拮抗活性。 进一步公开了包含作为活性成分的化合物的药物组合物。 药物组合物可用作中枢神经系统疾病的治疗和预防剂，其中需要针对5-HT7的拮抗活性，例如抑郁症，偏头痛，焦虑症，疼痛，炎性疼痛，神经性疼痛，体温调节异常，昼夜节律紊乱，睡眠 干扰和平滑肌相关疾病。